User login
Both statin and fibrate therapies taken to improve lipid profiles decreased the risk of stroke by 30% in a community-dwelling population of elderly people, according to prospective European study published online May 19 in the British Medical Journal.
Participants in almost all the randomized clinical trials assessing cardiovascular drugs are younger than age 70, so the benefits of these agents in older patients – particularly their effectiveness as primary prevention in people who have no known cardiovascular illness – is uncertain. Nevertheless, “in real life, statins are commonly prescribed to older people without clinical evidence of atherosclerosis,” said Dr. Annick Alperovitch of the University of Bordeaux (France) and her associates.
To assess the effects of statin and fibrate therapies on incident cardiovascular events in an elderly population, the investigators analyzed data from an ongoing cohort study of vascular disease among elderly residents of Bordeaux, Dijon, and Montpellier. Dr. Alperovitch and her associates examined the medical records of a subset of 7,484 men and women (mean age 74 years) who were followed every 2 years for a mean of 9 years. A total of 27% reported using lipid-lowering medications at baseline; roughly half used statins and half used fibrates. There were 292 strokes during follow-up.
The risk of stroke was cut by roughly 30% among statin and fibrate users, compared with nonusers (hazard ratio, 0.66). This decrease was similar between the two medications. All-cause mortality was slightly lower in people who took statins or fibrates, compared with nonusers (HR 0.87), the investigators said (Br. Med. J. 2015 May 19 [doi:10.1136/bmj.h2335]).
This is the first observational study to show a significant association between lipid-lowering drugs and decreased stroke risk, they noted.
The overall incidence of stroke in this study was low (0.47 per 100 person-years), so even a 30% decrease produced “a limited number of avoided cases.” That may be attributable in part to the generally healthy lifestyle, high educational achievement, and high economic status of this urban French study population. But if the findings are confirmed in future studies, they could have an important impact on public health in other populations, Dr. Alperovitch and her associates said.
The findings of a single observational study will not change guidelines regarding cholesterol therapy, but they are sufficiently compelling to warrant further research on primary prevention of stroke in elderly people.
This is the first observational study to describe a significant association between lipid-lowering medications and decreased stroke risk. Previous studies have shown only a weak association in early middle age, and no association in the elderly.
Graeme J. Hankey, M.D., is professor of neurology at the University of Western Australia’s Harry Perkins Institute of Medical Research, Perth, and honorary senior research fellow at Western Australian Neuroscience Research Institute, also in Perth. He reported ties to Sanofi Aventis, Bayer Pharmaceuticals, and Medscape. Dr. Hankey made these remarks in an editorial accompanying Dr. Alperovitch’s report (Br. Med. J. 2015 May 19 [doi:10.1136/bmj.h2568]).
The findings of a single observational study will not change guidelines regarding cholesterol therapy, but they are sufficiently compelling to warrant further research on primary prevention of stroke in elderly people.
This is the first observational study to describe a significant association between lipid-lowering medications and decreased stroke risk. Previous studies have shown only a weak association in early middle age, and no association in the elderly.
Graeme J. Hankey, M.D., is professor of neurology at the University of Western Australia’s Harry Perkins Institute of Medical Research, Perth, and honorary senior research fellow at Western Australian Neuroscience Research Institute, also in Perth. He reported ties to Sanofi Aventis, Bayer Pharmaceuticals, and Medscape. Dr. Hankey made these remarks in an editorial accompanying Dr. Alperovitch’s report (Br. Med. J. 2015 May 19 [doi:10.1136/bmj.h2568]).
The findings of a single observational study will not change guidelines regarding cholesterol therapy, but they are sufficiently compelling to warrant further research on primary prevention of stroke in elderly people.
This is the first observational study to describe a significant association between lipid-lowering medications and decreased stroke risk. Previous studies have shown only a weak association in early middle age, and no association in the elderly.
Graeme J. Hankey, M.D., is professor of neurology at the University of Western Australia’s Harry Perkins Institute of Medical Research, Perth, and honorary senior research fellow at Western Australian Neuroscience Research Institute, also in Perth. He reported ties to Sanofi Aventis, Bayer Pharmaceuticals, and Medscape. Dr. Hankey made these remarks in an editorial accompanying Dr. Alperovitch’s report (Br. Med. J. 2015 May 19 [doi:10.1136/bmj.h2568]).
Both statin and fibrate therapies taken to improve lipid profiles decreased the risk of stroke by 30% in a community-dwelling population of elderly people, according to prospective European study published online May 19 in the British Medical Journal.
Participants in almost all the randomized clinical trials assessing cardiovascular drugs are younger than age 70, so the benefits of these agents in older patients – particularly their effectiveness as primary prevention in people who have no known cardiovascular illness – is uncertain. Nevertheless, “in real life, statins are commonly prescribed to older people without clinical evidence of atherosclerosis,” said Dr. Annick Alperovitch of the University of Bordeaux (France) and her associates.
To assess the effects of statin and fibrate therapies on incident cardiovascular events in an elderly population, the investigators analyzed data from an ongoing cohort study of vascular disease among elderly residents of Bordeaux, Dijon, and Montpellier. Dr. Alperovitch and her associates examined the medical records of a subset of 7,484 men and women (mean age 74 years) who were followed every 2 years for a mean of 9 years. A total of 27% reported using lipid-lowering medications at baseline; roughly half used statins and half used fibrates. There were 292 strokes during follow-up.
The risk of stroke was cut by roughly 30% among statin and fibrate users, compared with nonusers (hazard ratio, 0.66). This decrease was similar between the two medications. All-cause mortality was slightly lower in people who took statins or fibrates, compared with nonusers (HR 0.87), the investigators said (Br. Med. J. 2015 May 19 [doi:10.1136/bmj.h2335]).
This is the first observational study to show a significant association between lipid-lowering drugs and decreased stroke risk, they noted.
The overall incidence of stroke in this study was low (0.47 per 100 person-years), so even a 30% decrease produced “a limited number of avoided cases.” That may be attributable in part to the generally healthy lifestyle, high educational achievement, and high economic status of this urban French study population. But if the findings are confirmed in future studies, they could have an important impact on public health in other populations, Dr. Alperovitch and her associates said.
Both statin and fibrate therapies taken to improve lipid profiles decreased the risk of stroke by 30% in a community-dwelling population of elderly people, according to prospective European study published online May 19 in the British Medical Journal.
Participants in almost all the randomized clinical trials assessing cardiovascular drugs are younger than age 70, so the benefits of these agents in older patients – particularly their effectiveness as primary prevention in people who have no known cardiovascular illness – is uncertain. Nevertheless, “in real life, statins are commonly prescribed to older people without clinical evidence of atherosclerosis,” said Dr. Annick Alperovitch of the University of Bordeaux (France) and her associates.
To assess the effects of statin and fibrate therapies on incident cardiovascular events in an elderly population, the investigators analyzed data from an ongoing cohort study of vascular disease among elderly residents of Bordeaux, Dijon, and Montpellier. Dr. Alperovitch and her associates examined the medical records of a subset of 7,484 men and women (mean age 74 years) who were followed every 2 years for a mean of 9 years. A total of 27% reported using lipid-lowering medications at baseline; roughly half used statins and half used fibrates. There were 292 strokes during follow-up.
The risk of stroke was cut by roughly 30% among statin and fibrate users, compared with nonusers (hazard ratio, 0.66). This decrease was similar between the two medications. All-cause mortality was slightly lower in people who took statins or fibrates, compared with nonusers (HR 0.87), the investigators said (Br. Med. J. 2015 May 19 [doi:10.1136/bmj.h2335]).
This is the first observational study to show a significant association between lipid-lowering drugs and decreased stroke risk, they noted.
The overall incidence of stroke in this study was low (0.47 per 100 person-years), so even a 30% decrease produced “a limited number of avoided cases.” That may be attributable in part to the generally healthy lifestyle, high educational achievement, and high economic status of this urban French study population. But if the findings are confirmed in future studies, they could have an important impact on public health in other populations, Dr. Alperovitch and her associates said.
Key clinical point: Statin and fibrate therapies significantly decreased stroke risk in a large cohort of elderly people.
Major finding: The risk of stroke was cut by 30% among statin and fibrate users, compared with nonusers (HR, 0.66).
Data source: A prospective, population-based cohort study of 7,484 elderly community-dwelling people followed for 9 years.
Disclosures: This study was supported by Institut National de la Sante et de la Recherche Medicale, Victor Segalen-Bordeaux II University, and Sanofi-Aventis. Dr. Alperovitch reported receiving honoraria from the French National Medicines Agency, the Fondation Plan Alzheimer, and Fondation Bettencourt-Schueller.
